{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:23Z","timestamp":1792683023650,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA72851, CA181572, CA187956, CA227602, CA214254, and CA271443"],"award-info":[{"award-number":["CA72851, CA181572, CA187956, CA227602, CA214254, and CA271443"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02526-0","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:44:39Z","timestamp":1763808279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A machine-learning powered liquid biopsy predicts response to paclitaxel plus ramucirumab in advanced gastric cancer: results from the prospective IVY trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Katsutoshi","family":"Shoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2526_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2526_CR2","doi-asserted-by":"crossref","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:167\u2013192.","DOI":"10.6004\/jnccn.2022.0008"},{"key":"2526_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"2526_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-masked, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"2526_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","volume":"6","author":"RH Xu","year":"2021","unstructured":"Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-masked, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:1015\u201324.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2526_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2019.10.026","volume":"127","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Muro K, Cunningham D, et al. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020;127:150\u20137.","journal-title":"Eur J Cancer"},{"key":"2526_CR7","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00280-019-03817-2","volume":"83","author":"M Natsume","year":"2019","unstructured":"Natsume M, Shimura T, Iwasaki H, et al. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer. Cancer Chemother Pharmacol. 2019;83:1037\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2526_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.critrevonc.2015.02.009","volume":"95","author":"G Aprile","year":"2015","unstructured":"Aprile G, Ongaro E, Del Re M, et al. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: a critical insight. Crit Rev Oncol Hematol. 2015;95:165\u201378.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2526_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-16-1676","volume":"23","author":"K Shigeyasu","year":"2017","unstructured":"Shigeyasu K, Toden S, Zumwalt TJ, et al. Emerging role of MicroRNAs as liquid biopsy biomarkers in gastrointestinal cancers. Clin Cancer Res. 2017;23(10):2391\u20139.","journal-title":"Clin Cancer Res"},{"key":"2526_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32:466\u201377.","journal-title":"Ann Oncol"},{"key":"2526_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-021-01396-6","volume":"20","author":"XH Tang","year":"2021","unstructured":"Tang XH, Guo T, Gao XY, et al. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer. 2021;20:99.","journal-title":"Mol Cancer"},{"key":"2526_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-019-0967-5","volume":"18","author":"T Huang","year":"2019","unstructured":"Huang T, Song C, Zheng L, et al. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol Cancer. 2019;18:62.","journal-title":"Mol Cancer"},{"key":"2526_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020. https:\/\/doi.org\/10.1126\/science.aau6977.","journal-title":"Science"},{"key":"2526_CR14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1186\/s12885-019-6163-6","volume":"19","author":"H Tanioka","year":"2019","unstructured":"Tanioka H, Nagasaka T, Uno F, et al. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY). BMC Cancer. 2019;19:941.","journal-title":"BMC Cancer"},{"key":"2526_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara K, Takashima A, Fujitani K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. The Lancet Gastroenterology & Hepatology. 2017;2:277\u201387.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2526_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejca.2017.11.032","volume":"91","author":"H Bando","year":"2018","unstructured":"Bando H, Shimodaira H, Fujitani K, et al. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer. 2018;91:86\u201391.","journal-title":"Eur J Cancer"},{"key":"2526_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41416-022-02138-1","volume":"128","author":"K Okuno","year":"2023","unstructured":"Okuno K, Watanabe S, Roy S, et al. A liquid biopsy signature for predicting early recurrence in patients with gastric cancer. Br J Cancer. 2023;128:1105\u201316.","journal-title":"Br J Cancer"},{"key":"2526_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/SLA.0000000000005473","volume":"276","author":"K Okuno","year":"2022","unstructured":"Okuno K, Tokunaga M, Kinugasa Y, et al. A transcriptomic liquid biopsy assay for predicting resistance to neoadjuvant therapy in esophageal squamous cell carcinoma. Ann Surg. 2022;276:101\u201310.","journal-title":"Ann Surg"},{"key":"2526_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2526_CR20","doi-asserted-by":"publisher","first-page":"W135","DOI":"10.1093\/nar\/gkw288","volume":"44","author":"Y Fan","year":"2016","unstructured":"Fan Y, Siklenka K, Arora SK, et al. Mirnet - dissecting miRNA-target interactions and functional associations through network-based visual analysis. Nucleic Acids Res. 2016;44:W135\u201341.","journal-title":"Nucleic Acids Res"},{"key":"2526_CR21","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264\u201379.","journal-title":"CA Cancer J Clin"},{"key":"2526_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","volume":"20","author":"M Alsina","year":"2023","unstructured":"Alsina M, Arrazubi V, Diez M, et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155\u201370.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2526_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"2526_CR24","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1571\u201380.","journal-title":"JAMA Oncol"},{"key":"2526_CR25","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438\u201344.","journal-title":"J Clin Oncol"},{"key":"2526_CR26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437\u201348.","journal-title":"Lancet Oncol"},{"key":"2526_CR27","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"2526_CR28","first-page":"3347","volume":"12","author":"L Fornaro","year":"2022","unstructured":"Fornaro L, Musettini G, Orlandi P, et al. Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer. Am J Cancer Res. 2022;12:3347\u201356.","journal-title":"Am J Cancer Res"},{"key":"2526_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/gutjnl-2021-324060","volume":"71","author":"R Sundar","year":"2022","unstructured":"Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al. Machine-learning model-derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut. 2022;71:676\u201385.","journal-title":"Gut"},{"key":"2526_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.7150\/ijbs.40338","volume":"16","author":"J Hou","year":"2020","unstructured":"Hou J, Zhuo H, Chen X, et al. Mir-139-5p negatively regulates PMP22 to repress cell proliferation by targeting the NF-\u03baB signaling pathway in gastric cancer. Int J Biol Sci. 2020;16:1218\u201329.","journal-title":"Int J Biol Sci"},{"key":"2526_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633366","volume":"11","author":"YJ Zhao","year":"2021","unstructured":"Zhao YJ, Zhang J, Wang YC, et al. MiR-450a-5p inhibits gastric cancer cell proliferation, migration, and invasion and promotes apoptosis via targeting CREB1 and inhibiting AKT\/GSK-3\u03b2 signaling pathway. Front Oncol. 2021;11:633366.","journal-title":"Front Oncol"},{"key":"2526_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clnu.2020.04.043","volume":"40","author":"Q Meng","year":"2021","unstructured":"Meng Q, Tan S, Jiang Y, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: a randomized clinical trial. Clin Nutr. 2021;40:40\u20136.","journal-title":"Clin Nutr"},{"key":"2526_CR33","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1245\/s10434-018-6452-3","volume":"25","author":"T Kawamura","year":"2018","unstructured":"Kawamura T, Makuuchi R, Tokunaga M, et al. Long-term outcomes of gastric cancer patients with preoperative sarcopenia. Ann Surg Oncol. 2018;25:1625\u201332.","journal-title":"Ann Surg Oncol"},{"key":"2526_CR34","doi-asserted-by":"publisher","first-page":"10116","DOI":"10.1038\/s41598-023-36968-7","volume":"13","author":"H Kamiya","year":"2023","unstructured":"Kamiya H, Komatsu S, Nishibeppu K, et al. Obesity paradox as a new insight from postoperative complications in gastric cancer. Sci Rep. 2023;13:10116.","journal-title":"Sci Rep"},{"key":"2526_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2018.1481321","volume":"7","author":"D Buschmann","year":"2018","unstructured":"Buschmann D, Kirchner B, Hermann S, et al. Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing. J Extracell Vesicles. 2018;7:1481321.","journal-title":"J Extracell Vesicles"},{"key":"2526_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512183","volume":"24","author":"M Llorens-Revull","year":"2023","unstructured":"Llorens-Revull M, Mart\u00ednez-Gonz\u00e1lez B, Quer J, Esteban JI, et al. Comparison of extracellular vesicle isolation methods for miRNA sequencing. Int J Mol Sci. 2023;24:12183.","journal-title":"Int J Mol Sci"},{"key":"2526_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413498","volume":"25","author":"E Piccinno","year":"2024","unstructured":"Piccinno E, Schirizzi A, Scalavino V, et al. Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as novel predictive biomarkers for ramucirumab-paclitaxel therapy outcomes in advanced gastric cancer. Int J Mol Sci. 2024;25:13498.","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02526-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:48:38Z","timestamp":1770900518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02526-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02526-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7059542\/v1","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. All procedures were approved by the Ethics Committee of Kawasaki Medical School. Written informed consent was obtained from all participants prior to enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}